南非结核病耐药检测中靶向下一代测序替代标准诊疗的成本效益
该研究使用决策树模型评估靶向下一代测序(tNGS)对比南非标准诊疗(SOC)在结核病耐药检测中的成本效益,并分析不同去中心化程度的影响。结果显示集中式tNGS相对SOC可节省成本,去中心化tNGS每避免一个DALY成本为671至2454美元,tNGS可缩短周转时间并提高耐药谱正确识别率。
要点
- 集中式tNGS相对SOC可节省成本,去中心化tNGS每避免一个DALY成本671至2454美元。
- tNGS正确识别90.7%的耐药谱,SOC为87.7%,并减少97年传染时间。
- 贝达喹啉耐药率越高、tNGS灵敏度越高,其相对SOC的成本效益越好。
核心结论
- 在南非,tNGS可节省成本(集中式)或具有成本效益(去中心化),并可能通过更短时间返回更多正确结果改善患者结局。
研究设计与样本
- 使用决策树模型评估tNGS对比SOC在南非不同tNGS去中心化程度下的成本效益。
主要发现
- tNGS避免408个DALY,正确识别90.7%的耐药谱,SOC为87.7%。
- tNGS缩短周转时间并避免97年传染时间。
- 集中式tNGS相对SOC节省成本,去中心化tNGS每避免一个DALY成本为671至2454美元。
- 贝达喹啉耐药率更高和tNGS灵敏度增加时,tNGS相对SOC的表现改善。
- 通过tNGS增加DST可及性可改善去中心化场景的成本效益。
临床怎么用
- 在南非可考虑集中式tNGS用于结核病耐药检测以节省成本。
- 去中心化tNGS虽成本增加但仍具成本效益,适用于需要快速结果的情景。
- 高贝达喹啉耐药率或高tNGS灵敏度条件下tNGS优势更明显。
局限性
- 分析基于模型假设,需在其他 settings 中重复验证以评估tNGS用于DST的更广泛可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: South Africa faces emerging resistance to tuberculosis drugs like bedaquiline. Phenotypic drug-susceptibility testing (DST), the current reference standard for bedaquiline DST, has long turnaround times. Targeted next-generation sequencing (tNGS) offers a comprehensive alternative, potentially delivering faster results. However, these advantages must be weighed against differences in cost and test accuracy. METHODS: We used a decision tree model to evaluate the cost-effectiveness of tNGS against the standard of care (SOC) in South Africa across different levels of tNGS decentralization. Key outcomes included survival rates, time to a correct resistance profile, infectious time, and disability-adjusted life years (DALYs). Sensitivity analyses assessed the impact of drug-resistance prevalence, tNGS sensitivity, and improved DST access on overall cost-effectiveness. RESULTS: tNGS averted 408 DALYs and correctly identified 90.7% of resistance profiles as compared to 87.7% with SOC. Based on model assumptions for South Africa, tNGS had a reduced turnaround time and averted 97 years of infectious time. Centralized tNGS was cost-saving relative to SOC; however, decentralization of tNGS resulted in higher costs per DALY averted ($671-$2454). tNGS performance, relative to the SOC, improved at higher bedaquiline resistance and with increased sensitivity. Any increase in DST access through tNGS would improve cost-effectiveness in decentralized scenarios. CONCLUSIONS: tNGS could be cost-saving (centralized) or cost-effective (decentralized) in South Africa and has the potential to improve patient outcomes by returning a greater number of correct results in a shorter time. This analysis should be replicated across other settings to evaluate the broader feasibility of tNGS for DST.
引用
- de Nooy A, Omar SV, Ockhuisen T, et al. Cost-effectiveness of Targeted Next-Generation Sequencing for Tuberculosis Drug-resistance Testing as an Alternative to the Standard of Care in South Africa. Clin Infect Dis. 2026. PMID: 40920587. doi:10.1093/cid/ciaf495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。